Inovio Pharmaceuticals (INO) reported a disappointing 3Q25 with a GAAP EPS loss of -$0.87, missing consensus by $0.45 and ...

Investors might want to bet on Inovio Pharmaceuticals (INO), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings ...

INOVIO Pharmaceuticals Inc. (NASDAQ:INO) shares fell 10% in early trading after the biotech company announced the pricing of ...

Investing.com -- INOVIO Pharmaceuticals Inc. (NASDAQ:INO) shares fell 10% after the biotechnology company announced the pricing of an underwritten public offering at $1.90 per share, representing a ...

This was the stock's fourth consecutive day of losses.

In addition to Piper Sandler, Inovio Pharmaceuticals also received a Buy from Oppenheimer’s Hartaj Singh in a report issued on November 11. However, on the same day, TR | OpenAI – 4o reiterated a Hold ...

The stock's rise snapped a four-day losing streak.

To get a sense of who is truly in control of Inovio Pharmaceuticals, Inc. (NASDAQ:INO), it is important to understand the ownership structure of the business. The group holding the most number of ...

US biotech Inovio (Nasdaq: INO) said it plans to offer and sell shares of its common stock in an underwritten public offering ...

Good afternoon, ladies and gentlemen, and welcome to the Inovio Third Quarter 2025 Financial Results Conference Call. [Operator Instructions] This call is being recorded on Monday, November 10, 2025.

INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today ...